HomeCompareZGNX vs O

ZGNX vs O: Dividend Comparison 2026

ZGNX yields 7.50% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $1.4K in total portfolio value· pulled ahead in Year 10
10 years
ZGNX
ZGNX
● Live price
7.50%
Share price
$26.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.8K
Annual income
$1,205.70
Full ZGNX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ZGNX vs O

📍 O pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZGNXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZGNX + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZGNX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZGNX
Annual income on $10K today (after 15% tax)
$637.18/yr
After 10yr DRIP, annual income (after tax)
$1,024.85/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $3,312.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZGNX + O for your $10,000?

ZGNX: 50%O: 50%
100% O50/50100% ZGNX
Portfolio after 10yr
$33.5K
Annual income
$3,154.22/yr
Blended yield
9.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ZGNX
No analyst data
Price Target
$26.00
-2.5% upside vs current
Range: $26.00 — $26.00
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZGNX buys
0
O buys
0
No recent congressional trades found for ZGNX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZGNXO
Forward yield7.50%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$32.8K$34.2K
Annual income after 10y$1,205.70$5,102.74
Total dividends collected$9.8K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst price target$26.00$64.00

Year-by-year: ZGNX vs O ($10,000, DRIP)

YearZGNX PortfolioZGNX Income/yrO PortfolioO Income/yrGap
1$11,450$749.63$10,818$608.16+$632.00ZGNX
2$13,053$802.14$11,787$741.68+$1.3KZGNX
3$14,822$854.66$12,946$911.00+$1.9KZGNX
4$16,766$906.96$14,345$1,127.94+$2.4KZGNX
5$18,899$958.83$16,056$1,409.05+$2.8KZGNX
6$21,232$1,010.08$18,171$1,777.83+$3.1KZGNX
7$23,778$1,060.53$20,820$2,268.21+$3.0KZGNX
8$26,553$1,110.04$24,188$2,929.90+$2.4KZGNX
9$29,570$1,158.47$28,533$3,837.11+$1.0KZGNX
10← crossover$32,846$1,205.70$34,235$5,102.74$1.4KO

ZGNX vs O: Complete Analysis 2026

ZGNXStock

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Full ZGNX Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ZGNX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZGNX vs SCHDZGNX vs JEPIZGNX vs KOZGNX vs MAINZGNX vs STAGZGNX vs ADCZGNX vs NNNZGNX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.